An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
NOVARTIS PHARMA AG
Cita
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib. (CLOU064A2306B). NOVARTIS PHARMA AG. 2026IP:MERCEDES RODRÍGUEZ SERNA.
Portal de investigación